Kairos Pharma, LTD Form 4 insider transactions

Kairos Pharma's Chief Scientific Officer, Neil Bhowmick, was granted 171,756 restricted stock units under the company's 2023 Equity Incentive Plan.

Kairos Pharma Director Hyun W. Bae reported the acquisition of 29,084 Restricted Stock Units under the company's 2023 Equity Incentive Plan.

Kairos Pharma's VP of Research and Development, Murali Ramachandran, was granted 152,672 restricted stock units under the company's 2023 Equity Incentive Plan.

Kairos Pharma Director Hansoo Michael Keyoung received grants of 29,084 Restricted Stock Units under the company's equity incentive plan.

Kairos Pharma Director Rahul Singhvi acquired 19,084 restricted stock units, vesting fully on the first anniversary of the grant date.

Kairos Pharma's Chief Financial Officer, Doug Samuelson, was granted 152,672 restricted stock units under the company's 2023 Equity Incentive Plan.

Kairos Pharma's CEO and Chairman, John S. Yu, reported the acquisition of 190,840 restricted stock units, increasing his beneficial ownership.

Neil Bhowmick, Chief Scientific Officer of Kairos Pharma, Ltd., reports the acquisition of 14,000 restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.

Ramachandran Murali, VP of Research and Development at Kairos Pharma, reports the acquisition of 14,000 restricted stock units.

John S Yu, CEO and Chairman of Kairos Pharma, reports the acquisition of 14,000 restricted stock units (RSUs) and provides an update on his beneficial ownership of the company's common stock.

Kairos Pharma's VP of Research and Development, Ramachandran Murali, purchased 200 shares of common stock at $1.59 per share on November 25, 2024.

Kairos Pharma's Chief Financial Officer, Doug Samuelson, purchased 2,500 shares of common stock at $1.50 per share on November 22, 2024.

Kairos Pharma's CEO and Chairman, John S. Yu, purchased 4,000 shares of common stock at $1.44 per share on November 20, 2024.